For decades, artificial intelligence advanced in careful, mostly linear steps. Researchers built models. Engineers improved performance. Organizations deployed systems to automate specific tasks. Each ...

Imagine Jo: Everyone in Jo's life recognizes her as an outstanding problem solver. She's the type of person who seems capable of almost anything. Jo excels at intuitive problem-solving. Over her life, ...

Shares of clinical-stage biotechnology company Recursion Pharmaceuticals (NASDAQ: RXRX) soared 11.43% on Wednesday, significantly outperforming the broader market. The rally followed a major analyst ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

SAN FRANCISCO – Basketball is often lauded as a game of skill. Gifted ball-handlers jet through the open court. Talented shooters turn slivers of space into spectacular shots. Deft passers transform ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren ...

Management reaffirmed guidance for 2025 on an expense base of less than $450 million, "excluding all of the partnership inflows." For 2026, guidance was also reaffirmed at less than $390 million.

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

The trend of AI researchers developing new, small open source generative models that outperform far larger, proprietary peers continued this week with yet another staggering advancement. The goal is ...